133 related articles for article (PubMed ID: 32322877)
1. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
Wang L; Allison D; Shukla PS
Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877
[TBL] [Abstract][Full Text] [Related]
2. MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas.
Shetty S; Habeeb O; Rivera C; Astbury C; Przybycin C; Joehlin-Price AS
Hum Pathol; 2021 Nov; 117():42-50. PubMed ID: 34391746
[TBL] [Abstract][Full Text] [Related]
3. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract][Full Text] [Related]
4. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
5. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
Mod Pathol; 2014 Feb; 27(2):231-7. PubMed ID: 23887305
[TBL] [Abstract][Full Text] [Related]
6. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
Ali RH; Seidman JD; Luk M; Kalloger S; Gilks CB
Int J Gynecol Pathol; 2012 Nov; 31(6):499-506. PubMed ID: 23018212
[TBL] [Abstract][Full Text] [Related]
7. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
8. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
9. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
10. Borderline Brenner Tumor: A Review of the Literature.
Zheng R; Heller DS
Arch Pathol Lab Med; 2019 Oct; 143(10):1278-1280. PubMed ID: 30779594
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases.
Jour G; West K; Ghali V; Shank D; Ephrem G; Wenig BM
Head Neck Pathol; 2013 Sep; 7(3):224-31. PubMed ID: 23315417
[TBL] [Abstract][Full Text] [Related]
12. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
13. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
15. HIF-1α, MDM2, CDK4, and p16 expression in ischemic fasciitis, focusing on its ischemic condition.
Yamada Y; Kinoshita I; Kohashi K; Yamamoto H; Kuma Y; Ito T; Koda K; Kisanuki A; Kurosawa M; Yoshimura M; Furue M; Oda Y
Virchows Arch; 2017 Jul; 471(1):117-122. PubMed ID: 28477272
[TBL] [Abstract][Full Text] [Related]
16. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
17. Significance of beta-catenin and pRB pathway components in malignant ovarian germ cell tumours: INK4A promoter CpG island methylation is associated with cell proliferation.
Kawauchi S; Liu XP; Kawasaki K; Hirakawa T; Amada S; Furuya T; Oga A; Sasaki K
J Pathol; 2004 Nov; 204(3):268-76. PubMed ID: 15476271
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
19. Inverse expression of Cdk4 and p16 in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Goto M; Inohara T; Sugimoto K; Tai Y; Hando T; Tokuda M
Gynecol Oncol; 2000 Nov; 79(2):230-7. PubMed ID: 11063650
[TBL] [Abstract][Full Text] [Related]
20. Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study.
De Cecio R; Cantile M; Collina F; Marra L; Santonastaso C; Scaffa C; Botti G; Losito NS
J Ovarian Res; 2014 Oct; 7():101. PubMed ID: 25358264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]